ACADIA Pharmaceuticals Inc at SVB Leerink Global Healthcare Conference (Virtual) Transcript
Okay. Welcome back to our next session at the SVB Leerink Global Healthcare Conference. I'm Marc Goodman, one of the biopharma analysts. And we're lucky to have ACADIA Pharmaceuticals next. The management team joining us. And we have Steve Davis, CEO. For the past 6 years. We have Serge Stankovic, who is the President, but also Head of R&D, as everybody knows, the past 6 years; and Elena Ridloff, who joined the company 3 years ago and is currently the CFO. Thank you, all 3 of you, for joining us. And Steve, I'll let you make some opening comments before we jump into Q&A.
Yes. Great. Thanks much, Marc.
So just to level set with everyone. First, I'd like to start by highlighting our key accomplishments in 2020 and touch on a few expectations for 2021, as we execute our business across 3 strategic pillars. First, we're driving NUPLAZID growth in PDP. In 2020, we achieved net
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
